Roivant Sciences (ROIV) Free Cash Flow (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Free Cash Flow came in at -$593.5 million in Q4 2025, up 11.51% YoY from -$532.2 million in Q4 2024, and down 206.69% on a QoQ basis from -$193.5 million in Q3 2025.
Roivant Sciences (ROIV) Free Cash Flow (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Free Cash Flow data on file, last reported at -$593.5 million in Q4 2025.
- Quarterly Free Cash Flow rose 11.51% year-over-year to -$593.5 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$995.4 million (up 12.09% YoY) and the FY2026 annual result came in at -$757.8 million, up 10.22% from the prior year.
- Free Cash Flow slipped to -$593.5 million in Q4 2025, from -$193.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$123.4 million in Q3 2021 to a low of -$675.4 million in Q4 2022.
- A 5-year average of -$344.6 million and a median of -$250.3 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2021 — Free Cash Flow slumped 199.26% — and 2025, when it rose 27.74%.
- Tracing ROIV's Free Cash Flow over 5 years: stood at -$541.4 million in 2021, then slipped by 24.74% to -$675.4 million in 2022, then increased by 2.6% to -$657.8 million in 2023, then fell by 1.95% to -$670.7 million in 2024, then increased by 11.51% to -$593.5 million in 2025.
- The last three Free Cash Flow figures came in at -$593.5 million (Q4 2025), -$193.5 million (Q3 2025), and -$208.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -268.64 Mn |
| Jun 30, 2026 | -268.64 Mn |
| Dec 31, 2025 | -593.48 Mn |
| Dec 31, 2025 | -593.48 Mn |
| Sep 30, 2025 | -193.51 Mn |
| Sep 30, 2025 | -193.51 Mn |
| Jun 30, 2025 | -208.42 Mn |
| Jun 30, 2025 | -208.42 Mn |
| Dec 31, 2024 | -670.67 Mn |
| Dec 31, 2024 | -670.67 Mn |
| Sep 30, 2024 | -267.80 Mn |
| Sep 30, 2024 | -267.80 Mn |
| Jun 30, 2024 | -193.79 Mn |
| Jun 30, 2024 | -193.79 Mn |
| Dec 31, 2023 | -657.84 Mn |
| Dec 31, 2023 | -657.84 Mn |
| Sep 30, 2023 | -196.70 Mn |
| Sep 30, 2023 | -196.70 Mn |
| Jun 30, 2023 | -250.34 Mn |
| Jun 30, 2023 | -250.34 Mn |